Clinical Protocol and Data Management
Clinical Protocol and Data Management
批准号:
10113628
负责人:
SHAJI Kunnathu KUMAR
金额:
$55.79万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1997
资助国家:
美国
项目状态:
已结题
起止时间:
1997-04-25 至 2024-02-29
关键词:
AddressAdverse eventAffectArizonaCase Report FormCatchment AreaCell TherapyChildClinicClinical Cancer CenterClinical DataClinical InvestigatorClinical ProtocolsClinical ResearchClinical TrialsClinical Trials Data Monitoring CommitteesCollectionComplexComprehensive Cancer CenterConduct Clinical TrialsConsent FormsDataData CollectionDevelopmentDiseaseEnrollmentEnsureFloridaGrantGrowthHealth systemImmune checkpoint inhibitorIndividualInformation ManagementInstitutional PolicyInstitutional Review BoardsInterventionIntervention StudiesMaintenanceMalignant NeoplasmsMayo Clinic Cancer CenterMidwestern United StatesMinorMonitorOffice ManagementOperations ResearchPhysician ExecutivesPoliceProcessProtocols documentationRecordsRegulationReportingResearch DesignResearch PersonnelResearch SubjectsRural PopulationSafetyServicesStandardizationSystemTherapeuticTimeToxic effectTrainingUnderrepresented PopulationsWomanWorkbasecancer clinical trialcell growthchimeric antigen receptor T cellsdata managementdata qualitydata quality/integritydemographicsethnic minority populationimprovedinnovationmemberminority childrennovelparticipant safetypatient safetyprogramsracial minorityresponsetargeted treatmenttrend
中文摘要
点击翻译按钮获取中文摘要
英文摘要
CLINICAL PROTOCOL AND DATA MANAGEMENT PROJECT SUMMARY
The Mayo Clinic Cancer Center (MCCC) Clinical Protocol and Data Management (CPDM) functions are
administratively overseen by the MCCC Clinical Research Committee (Chaired by the MCCC Deputy Director
for Clinical Research) and functionally coordinated by the MCCC Clinical Research Office (CRO), the Data and
Safety Monitoring Committee (DSMC), and the Data and Safety Monitoring Board (DSMB). The CPDM
functions include clinical research operations and data quality monitoring, facilitated by the Medical Director
and Administrative Director and supported by the CRO staff. The CRO carries out development, activation,
study maintenance, study coordination, administration, and reporting for all cancer clinical trials conducted at
the MCCC. In addition, the CRO provides operational support for the Protocol Review and Monitoring System
(PRMS) and the Data and Safety Monitoring (DSM) System. The CPDM and DSM functions at MCCC are
distinct from PRMS functions, with minor overlap of membership. Staff in the CRO work collaboratively with the
MCCC clinical investigators to provide expert, efficient support in the conduct of clinical research across the
enterprise and with individual Disease Groups to ensure efficient development and activation of clinical trials
consistent with the priorities of the MCCC Programs.
Over the past grant period, the CRO has overseen the development and activation of 617 studies, including an
increasingly complex portfolio of studies (e.g., checkpoint inhibitors, CAR T-cells, basket and umbrella trials
with targeted therapies). It has provided staffing support in alignment with the growth of the Disease Groups,
facilitated the opening of a wide variety of trials in line with Disease Group growth strategies, and maintained
stable clinical trial accrual volumes over the last 3 years. With the creation of the integrated Early Cancer
Therapeutics (ECTx) unit and the growth of the Cellular Therapy Disease Group, the CRO continues to evolve
to efficiently support novel, complex, and innovative trials. Significant progress has been made to improve the
clinical trial activation process to address efficiency, time to activation, and quality. Ongoing developments will
include the implementation of a new clinical research management system.
MCCC provides oversight for participant safety through the Center's DSM system, with functions carried out by
the DSMC and the DSMB. The DSMC focuses broadly on safety rather than on individual studies. It evaluates
trends in protocol deviations and toxicities and recommends MCCC-wide procedural changes aimed at
ensuring that studies are conducted in accordance with MCCC's Data Safety and Monitoring Plan and with
federal, local, and institutional policies. The DSMC also reviews the DSM Plan annually and oversees the
DSMB functions. The DSMB focuses their review on individual studies, ensuring patient safety by regularly
reviewing adverse events on study and responses to the study intervention for individual trials.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The Role of Cereblon Pathways in Myeloma
-
批准号:9024349
-
项目类别:
-
资助金额:$44.63万
-
财政年份:2014
-
负责人:SHAJI Kunnathu KUMAR
-
依托单位:
The Role of Cereblon Pathways in Myeloma
-
批准号:8669613
-
项目类别:
-
资助金额:$49.46万
-
财政年份:2014
-
负责人:SHAJI Kunnathu KUMAR
-
依托单位:
Onset and biomarkers for progression of monoclonal gammopathies
-
批准号:8342326
-
项目类别:
-
资助金额:$32.99万
-
财政年份:2012
-
负责人:SHAJI Kunnathu KUMAR
-
依托单位:
Onset and biomarkers for progression of monoclonal gammopathies
-
批准号:8512677
-
项目类别:
-
资助金额:$31.01万
-
财政年份:2012
-
负责人:SHAJI Kunnathu KUMAR
-
依托单位:
Onset and biomarkers for progression of monoclonal gammopathies
-
批准号:10206030
-
项目类别:
-
资助金额:$9.48万
-
财政年份:2012
-
负责人:SHAJI Kunnathu KUMAR
-
依托单位:
Onset and biomarkers for progression of monoclonal gammopathies
-
批准号:10656463
-
项目类别:
-
资助金额:$41.4万
-
财政年份:2012
-
负责人:SHAJI Kunnathu KUMAR
-
依托单位:
Onset and biomarkers for progression of monoclonal gammopathies
-
批准号:8846552
-
项目类别:
-
资助金额:$32.99万
-
财政年份:2012
-
负责人:SHAJI Kunnathu KUMAR
-
依托单位:
Onset and biomarkers for progression of monoclonal gammopathies
-
批准号:10471179
-
项目类别:
-
资助金额:$43.45万
-
财政年份:2012
-
负责人:SHAJI Kunnathu KUMAR
-
依托单位:
Prevalence and Progression of Monoclonal Gammopathies
-
批准号:9015415
-
项目类别:
-
资助金额:$32.2万
-
财政年份:2004
-
负责人:SHAJI Kunnathu KUMAR
-
依托单位:
Prevalence and Progression of Monoclonal Gammopathies
-
批准号:8692316
-
项目类别:
-
资助金额:$32.2万
-
财政年份:2004
-
负责人:SHAJI Kunnathu KUMAR
-
依托单位:
Clinical Protocol and Data Management
-
批准号:10362661
-
项目类别:
-
资助金额:$55.8万
-
财政年份:1997
-
负责人:SHAJI Kunnathu KUMAR
-
依托单位:
海外基金